<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005613</url>
  </required_header>
  <id_info>
    <org_study_id>11306</org_study_id>
    <secondary_id>MCC-11306</secondary_id>
    <secondary_id>IRB-4250</secondary_id>
    <secondary_id>NCI-G00-1746</secondary_id>
    <nct_id>NCT00005613</nct_id>
  </id_info>
  <brief_title>Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease</brief_title>
  <acronym>CBV</acronym>
  <official_title>A Prospective, Comparative Trial of Allogeneic Versus Autologous Stem Cell Transplantation for High Risk Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining chemotherapy with allogeneic or autologous peripheral
      stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and
      kill more cancer cells.

      PURPOSE: Phase II trial to compare the effectiveness of allogeneic stem cell transplantation
      with that of autologous peripheral stem cell transplantation in treating patients who have
      non-Hodgkin's lymphoma or Hodgkin's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare the relapse rate, progression free survival, and overall survival in
      patients with high risk non-Hodgkin's lymphoma or Hodgkin's disease treated with allogeneic
      vs autologous stem cell transplantation. II. Compare the toxicities (short and long term) of
      these 2 regimens in these patients.

      OUTLINE: Cytoreductive therapy: Patients receive 3 courses of salvage chemotherapy (e.g.,
      dexamethasone, high dose cytarabine, and cisplatin (DHAP); etoposide, methylprednisolone,
      high dose cytarabine, and cisplatin (ESHAP); fludarabine, mitoxantrone, and dexamethasone
      (FND)). Harvest: Patients with an HLA identical sibling donor are assigned to the allogeneic
      peripheral blood stem cell (PBSC) transplantation group. Patients without an HLA identical
      sibling are assigned to the autologous PBSC transplantation group. Allogeneic OR autologous
      PBSC are harvested. Conditioning regimen: Patients receive high dose chemotherapy comprised
      of cyclophosphamide IV over 1 hour on days -6 to -3 and carmustine IV over 3 hours and
      etoposide IV over 3 hours on days -6 to -4. PBSC are infused on day 0. Patients are followed
      weekly for 3 months, then monthly for 1 year, and then annually thereafter.

      PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study over 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1996</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relapse rate</measure>
    <time_frame>5 years</time_frame>
    <description>determine relapse rate after allogeneic versus autologous hematopoietic progenitor cell transplantation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Autologous Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologous hematopoietic progenitor cell transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allogeneic Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>allogeneic hematopoietic progenitor cell trasnplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Cyclophosphamide will be given at a dose of 1500 mg/m2/day IV over 1.0 hour on days -6, -5, -4, and -3.</description>
    <arm_group_label>Autologous Transplant</arm_group_label>
    <arm_group_label>Allogeneic Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Etoposide will be given at a dose of 600 mg/m2/day over 3.0 hours on days -6, -5, and -4.</description>
    <arm_group_label>Autologous Transplant</arm_group_label>
    <arm_group_label>Allogeneic Transplant</arm_group_label>
    <other_name>vp-16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCNU</intervention_name>
    <description>BCNU will be given at a dose of 150 mg/m2/day in 500 cc D5W over 3.0 hours on days -6, -5, and -4</description>
    <arm_group_label>Autologous Transplant</arm_group_label>
    <arm_group_label>Allogeneic Transplant</arm_group_label>
    <other_name>Carmustine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven non-Hodgkin's lymphoma that has relapsed or
        failed to achieve complete remission after first line induction chemotherapy Intermediate
        or high grade (including mantle cell, but excluding lymphoblastic disease) No more than 1
        prior salvage chemotherapy regimen, e.g.: Dexamethasone, high dose cytarabine, and
        cisplatin (DHAP) Etoposide, methylprednisolone, high dose cytarabine, and cisplatin (ESHAP)
        Low grade No more than 2 prior salvage chemotherapy regimens, e.g.: Fludarabine,
        mitoxantrone, and dexamethasone (FND) ESHAP DHAP OR Histologically proven stage III or IV
        Hodgkin's disease that has relapsed or failed to achieve remission after combination
        induction chemotherapy Prior primary radiotherapy allowed if relapse is high risk (e.g.,
        recurrence in radiation field, B symptoms, liver/marrow involvement) No more than 2 prior
        salvage chemotherapy regimens Allogeneic stem cell transplantation group: Availability of 6
        antigen (A, B, and DR loci) HLA matched sibling donor No active CNS disease A new
        classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The
        terminology of &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace the former terminology of
        &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol uses the former
        terminology.

        PATIENT CHARACTERISTICS: Age: 15 to 55 Performance status: ECOG 0 or 1 Life expectancy: Not
        specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT
        and SGPT no greater than 3 times normal PT and PTT normal Renal: Creatinine no greater than
        2.0 mg/dL Creatinine clearance at least 60 mL/min Cardiovascular: LVEF at least 45% by MUGA
        scan or echocardiogram No myocardial infarction within the past 6 months No arrhythmias
        unless medically controlled Pulmonary: FEV1 at least 50% predicted DLCO at least 50%
        predicted Other: No diabetes mellitus or thyroid disease unless medically controlled No
        active serious infection HIV negative Not pregnant or nursing Negative pregnancy test

        PRIOR CONCURRENT THERAPY: See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven C. Goldstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2000</study_first_submitted>
  <study_first_submitted_qc>June 24, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2004</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

